Improved molecular diagnostics is of indispensable value for detecting clinical disease cases and carriage of EHEC/STEC. With the advent of the novel diagnostics, however, there is a need for agreeing on diagnostic criteria and on how to handle infection ranging from asymptomatic carriage to severe clinical disease. This working group was created to provide a platform for discussing these issues in a Nordic context.

Contact: Andreas Matussek, Head of Karolinska Universitetslaboratoriet, Stockholm, Sweden.